Hancock Whitney’s Medifast MED Stock Holding History

Hancock Whitney’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,368	Closed	-$286K	–	705
2021 Q4	$286K	Buy	1,368 +1	+0.1%	+$207	0.01%	602
2021 Q3	$262K	Sell	1,367 -10	-0.7%	-$2.46K	0.01%	596
2021 Q2	$389K	Buy	1,377 +24	+2%	+$6.5K	0.01%	620
2021 Q1	$286K	Sell	1,353 -89	-6%	-$21.3K	0.01%	654
2020 Q4	$283K	Sell	1,442 -92	-6%	-$16.3K	0.01%	658
2020 Q3	$252K	Hold	1,534	–	–	0.01%	669
2020 Q2	$213K	Buy	+1,534	New	+$141K	0.01%	699
2017 Q2	–	Sell	-17,100	Closed	-$759K	–	579
2017 Q1	$759K	Hold	17,100	–	–	0.03%	389
2016 Q4	$712K	Buy	+17,100	New	+$689K	0.03%	422
2015 Q4	–	Sell	-21,800	Closed	-$586K	–	558
2015 Q3	$586K	Buy	+21,800	New	+$635K	0.02%	419
2014 Q2	–	Sell	-19,690	Closed	-$573K	–	516
2014 Q1	$573K	Buy	+19,690	New	+$527K	0.02%	341

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Hancock Whitney's MED Position: Q1 2022 in Review

Hancock Whitney sold out of Medifast (MED) in Q1 2022, closing a stake of 1,368 shares — an estimated $286K sold.

Hancock Whitney first reported a position in MED in Q1 2014 and held it in 11 quarters. The position peaked at $759K in Q1 2017. 288 funds tracked by Wall St. Rank hold MED as of Q1 2022.

Hancock Whitney reported no remaining Medifast position as of Q1 2022 after selling out during the quarter.
Hancock Whitney sold 1,368 Medifast shares in Q1 2022, an estimated $286K.
Hancock Whitney first reported a position in Medifast in Q1 2014 and held it in 11 quarters.
Hancock Whitney's Medifast position peaked at $759K in Q1 2017.
288 funds tracked by Wall St. Rank held Medifast as of Q1 2022.

Based on Hancock Whitney's 13F filing for Q1 2022, filed 12 May 2022.